

Enriqueta Felip, MD, PhD

Positions:

Head Thoracic and H&N Cancer Group, Vall d'Hebron Institute of Oncology (VHIO)
Head Thoracic Tumors Unit, Oncology Department, Vall d'Hebron University Hospital
Associate Professor, Medicine Department, Autonomous University of Barcelona

Personal Statement:

Professor Felip is in charge of thoracic malignancy management, and is responsible for thoracic cancer trials undertaken by the Oncology Department. She received her medical degree from the Autonomous University of Barcelona, where she also completed her PhD in medical oncology. She is currently a member of the Spanish Lung Cancer Group (SLCG), the Spanish Society of Medical Oncology (SEOM), the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (IASLC) and the National Lung Cancer Partnership. She is the coordinator of the lung cancer program of the European School of Oncology (ESO). She is especially interested in the evaluation of new pharmaceutical entities, including immune checkpoint inhibitors or targeted therapies and the development of new tools to improve patient's treatment options like PDX or blood based assays. Her active contribution to the development of immunotherapies has allowed her to sign the most relevant publications regarding clinical development of them (Herbst RS, et al. *Lancet*. 2016; Borghaei H, et al. *NEJM*. 2015 among others). She is principal investigator of several clinical trials with immune checkpoint inhibitors and some translational projects, which include the identification of new patient populations, the study of mechanism of resistance to targeted therapies and, more recently, the study of different blood fractions to be used as diagnostic and follow-up tools. Most relevant/recent peer-reviewed publications (last 5 years):

1. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. 2016. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. **Lancet**. 387(10027):1540-50.
2. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufel M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. 2015. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. **N Engl J Med**. 373(17):1627-39.
3. Garon EB; Rizvi NA; Hui R; Leighl N; Balmanoukian AS; Eder JP; Patnaik A; Aggarwal C; Gubens M; Horn L; Carcereny E; Ahn MJ; Felip E; Lee JS; Hellmann MD; Hamid O; Goldman JW; Soria JC; Dolled-Filhart M; Rutledge RZ; Zhang J; Luceford JK; Rangwala R; Lubiniecki GM; Roach C; Emancipator K; Gandhi L. 2015. Pembrolizumab for the treatment of non-small-cell lung cancer. **N Engl J Med**. 372: 2018-2028.
4. Jänne PA; Yang JC; Kim DW; Planchard D; Ohe Y; Ramalingam SS; Ahn MJ; Kim SW; Su WC; Horn L; Haggstrom D; Felip E; Kim JH; Frewer P; Cantarini M; Brown KH; Dickinson PA; Ghiorghiu S; Ranson M. 2015. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. **N Engl J Med**. 372: 1689-1699.
5. Thress KS; Paweletz CP; Felip E; Cho BC; Stetson D; Dougherty B; Lai Z; Markovets A; Vivancos A; Kuang Y; Ercan D; Matthews SE; Cantarini M; Barrett JC; Jänne PA; Oxnard GR. 2015. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. **Nat Med**. 21: 560-562.